Medical Health & Life Science Research News

Explore osteoarthritis - pipeline review, H2 2017

Medical Market Research

A new research document with title 'Osteoarthritis - Pipeline Review, H2 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Corestem Inc, Dong-A Socio Holdings Co Ltd, Eli Lilly and Company. The report will help user gain market insights, future trends and growth prospects for forecast.

The latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation.

Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Request a sample report @…pipeline-review-1

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 16, 9, 44 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 5 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Access this report @…amp;report=653566

Reasons to access

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

4P-Pharma SAS
AbbVie Inc
Abiogen Pharma SpA
Ablynx NV
Amgen Inc
Amura Holdings Ltd
Anterogen Co Ltd
Asahi Kasei Pharma Corp
Axsome Therapeutics Inc
Biopharm GmbH
Bone Therapeutics SA
Can-Fite BioPharma Ltd
Cardax Inc
Cellular Biomedicine Group Inc
Corestem Inc
Dong-A Socio Holdings Co Ltd
Eli Lilly and Company
Evgen Pharma Plc
Galapagos NV
Gemphire Therapeutics Inc
Genequine Biotherapeutics GmbH
GlaxoSmithKline Plc
InKemia IUCT Group SA
International Stem Cell Corp
Jeil Pharmaceutical Co Ltd
K-Stemcell Co Ltd
Kang Stem Biotech Co Ltd
Lateral Pharma Pty Ltd
Levolta Pharmaceuticals Inc
LG Chem, Ltd.
Marina Biotech Inc
Medivir AB
Merck KGaA
Mesoblast Ltd
Mor Research Application Ltd
Nordic Bioscience A/S
Novartis AG
NovelMed Therapeutics Inc
Osteologix Holdings Plc
Pfizer Inc
Pharmalink AB
Philogen SpA
PhytoHealth Corp
PLx Pharma Inc
ProteoThera Inc
Regeneus Ltd
Regulaxis SAS
Rottapharm Biotech Srl
Samumed LLC
Seikagaku Corp
Stelis Biopharma Pvt Ltd
Takeda Pharmaceutical Company Ltd
TissueGene Inc
Traverse Biosciences Inc
Unity Biotechnology Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zimmer Biomet Holdings Inc

Get report @…pipeline-review-1

Table of Contents

Introduction 6
Osteoarthritis - Overview 7
Osteoarthritis - Therapeutics Development 8
Osteoarthritis - Therapeutics Assessment 21
Osteoarthritis - Companies Involved in Therapeutics Development 31
Osteoarthritis - Drug Profiles 61
Osteoarthritis - Dormant Projects 213
Osteoarthritis - Discontinued Products 219
Osteoarthritis - Product Development Milestones 221
Appendix 229List of Tables
Number of Products under Development for Osteoarthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017


View Detailed Table of Content @…pipeline-review-1

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.